Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Structures of REV1 UBM2 Domain Complex with Ubiquitin and with a Small-Molecule that Inhibits the REV1 UBM2-Ubiquitin Interaction.

Vanarotti M, Grace CR, Miller DJ, Actis ML, Inoue A, Evison BJ, Vaithiyalingam S, Singh AP, McDonald ET, Fujii N.

J Mol Biol. 2018 Aug 17;430(17):2857-2872. doi: 10.1016/j.jmb.2018.05.042. Epub 2018 Jun 2.

PMID:
29864443
2.

Small-molecules that bind to the ubiquitin-binding motif of REV1 inhibit REV1 interaction with K164-monoubiquitinated PCNA and suppress DNA damage tolerance.

Vanarotti M, Evison BJ, Actis ML, Inoue A, McDonald ET, Shao Y, Heath RJ, Fujii N.

Bioorg Med Chem. 2018 May 15;26(9):2345-2353. doi: 10.1016/j.bmc.2018.03.028. Epub 2018 Mar 19.

3.

Identification of the first small-molecule inhibitor of the REV7 DNA repair protein interaction.

Actis ML, Ambaye ND, Evison BJ, Shao Y, Vanarotti M, Inoue A, McDonald ET, Kikuchi S, Heath R, Hara K, Hashimoto H, Fujii N.

Bioorg Med Chem. 2016 Sep 15;24(18):4339-4346. doi: 10.1016/j.bmc.2016.07.026. Epub 2016 Jul 16.

4.

A clickable psoralen to directly quantify DNA interstrand crosslinking and repair.

Evison BJ, Actis ML, Fujii N.

Bioorg Med Chem. 2016 Mar 1;24(5):1071-8. doi: 10.1016/j.bmc.2016.01.032. Epub 2016 Jan 18.

6.

A novel assay revealed that ribonucleotide reductase is functionally important for interstrand DNA crosslink repair.

Fujii N, Evison BJ, Actis ML, Inoue A.

Bioorg Med Chem. 2015 Nov 1;23(21):6912-21. doi: 10.1016/j.bmc.2015.09.045. Epub 2015 Sep 30.

7.

Mitoxantrone, More than Just Another Topoisomerase II Poison.

Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM.

Med Res Rev. 2016 Mar;36(2):248-99. doi: 10.1002/med.21364. Epub 2015 Aug 19. Review.

PMID:
26286294
8.

Design, synthesis, and DNA sequence selectivity of formaldehyde-mediated DNA-adducts of the novel N-(4-aminobutyl) acridine-4-carboxamide.

Ankers EA, Evison BJ, Phillips DR, Brownlee RTC, Cutts SM.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5710-5715. doi: 10.1016/j.bmcl.2014.10.062. Epub 2014 Oct 23.

PMID:
25453806
9.

A site-selective, irreversible inhibitor of the DNA replication auxiliary factor proliferating cell nuclear antigen (PCNA).

Evison BJ, Actis ML, Wu SZ, Shao Y, Heath RJ, Yang L, Fujii N.

Bioorg Med Chem. 2014 Nov 15;22(22):6333-43. doi: 10.1016/j.bmc.2014.09.058. Epub 2014 Oct 8.

10.

A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin.

Inoue A, Kikuchi S, Hishiki A, Shao Y, Heath R, Evison BJ, Actis M, Canman CE, Hashimoto H, Fujii N.

J Biol Chem. 2014 Mar 7;289(10):7109-20. doi: 10.1074/jbc.M113.520429. Epub 2014 Jan 28.

11.

The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.

Forrest RA, Swift LP, Evison BJ, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Cancer Chemother Pharmacol. 2013 Mar;71(3):809-16. doi: 10.1007/s00280-012-2049-x. Epub 2012 Dec 23.

PMID:
23263186
12.

M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.

Evison BJ, Pastuovic M, Bilardi RA, Forrest RA, Pumuye PP, Sleebs BE, Watson KG, Phillips DR, Cutts SM.

Biochem Pharmacol. 2011 Dec 1;82(11):1604-18. doi: 10.1016/j.bcp.2011.08.013. Epub 2011 Aug 30.

PMID:
21889927
13.

DNA binding by pixantrone.

Adnan N, Buck DP, Evison BJ, Cutts SM, Phillips DR, Collins JG.

Org Biomol Chem. 2010 Dec 7;8(23):5359-66. doi: 10.1039/c0ob00295j. Epub 2010 Sep 24.

PMID:
20865205
14.

New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.

Mansour OC, Evison BJ, Sleebs BE, Watson KG, Nudelman A, Rephaeli A, Buck DP, Collins JG, Bilardi RA, Phillips DR, Cutts SM.

J Med Chem. 2010 Oct 14;53(19):6851-66. doi: 10.1021/jm901894c.

PMID:
20860366
15.

In vitro transcription assay for resolution of drug-DNA interactions at defined DNA sequences.

Evison BJ, Phillips DR, Cutts SM.

Methods Mol Biol. 2010;613:207-22. doi: 10.1007/978-1-60327-418-0_13.

PMID:
19997886
16.

CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity.

Evison BJ, Bilardi RA, Chiu FC, Pezzoni G, Phillips DR, Cutts SM.

Nucleic Acids Res. 2009 Oct;37(19):6355-70. doi: 10.1093/nar/gkp700. Epub 2009 Aug 31.

17.

Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets.

Evison BJ, Chiu F, Pezzoni G, Phillips DR, Cutts SM.

Mol Pharmacol. 2008 Jul;74(1):184-94. doi: 10.1124/mol.108.045625. Epub 2008 Apr 15.

PMID:
18413664
18.

Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.

Evison BJ, Mansour OC, Menta E, Phillips DR, Cutts SM.

Nucleic Acids Res. 2007;35(11):3581-9. Epub 2007 May 5.

19.

A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences.

Parker BS, Buley T, Evison BJ, Cutts SM, Neumann GM, Iskander MN, Phillips DR.

J Biol Chem. 2004 Apr 30;279(18):18814-23. Epub 2004 Feb 12.

Supplemental Content

Loading ...
Support Center